Literature DB >> 16497727

Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c).

Daniel R Scoles1, William H Yong, Yun Qin, Kolja Wawrowsky, Stefan Matthias Pulst.   

Abstract

The neurofibromatosis 2 (NF2) tumor suppressor protein, schwannomin or merlin, is commonly lost upon NF2 gene mutation in benign human brain tumors. We identified the p110 subunit of the eukaryotic initiation factor 3 (eIF3c) as a schwannomin interacting protein. The eIF3 complex consists of approximately 10 subunits whose functions are only recently becoming known. Interaction between schwannomin and eIF3c suggests a role for schwannomin in eIF3c-mediated regulation of proliferation related to changes in protein translation. We found that schwannomin was most effective for inhibiting cellular proliferation when eIF3c was highly expressed. When we examined these proteins in 14 meningiomas, we observed high eIF3c abundance in those that had lost schwannomin expression but low eIF3c abundance in those retaining schwannomin. Consequently, eIF3c appears to be involved in NF2 pathogenesis and deserves to be investigated as a prognostic marker for NF2 and target for treatment of NF2 patient tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16497727     DOI: 10.1093/hmg/ddl021

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  21 in total

Review 1.  Translational control in cancer.

Authors:  Deborah Silvera; Silvia C Formenti; Robert J Schneider
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

2.  Analysis of cytogenetic aberrations in sporadic vestibular schwannoma by comparative genomic hybridization.

Authors:  Dimitrios Koutsimpelas; Uwe Felmeden; Wolf J Mann; Jürgen Brieger
Journal:  J Neurooncol       Date:  2010-09-26       Impact factor: 4.130

Review 3.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

4.  Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.

Authors:  Janet L Oblinger; Sarah S Burns; Jie Huang; Li Pan; Yulin Ren; Rulong Shen; A Douglas Kinghorn; D Bradley Welling; Long-Sheng Chang
Journal:  Exp Neurol       Date:  2017-06-10       Impact factor: 5.330

5.  The oncogenic role of EIF3D is associated with increased cell cycle progression and motility in prostate cancer.

Authors:  Yi Gao; Jingfei Teng; Yi Hong; Fajun Qu; Jizhong Ren; Lin Li; Xiuwu Pan; Lu Chen; Lei Yin; Danfeng Xu; Xingang Cui
Journal:  Med Oncol       Date:  2015-06-03       Impact factor: 3.064

6.  RNA interference-mediated silencing of eukaryotic translation initiation factor 3, subunit B (EIF3B) gene expression inhibits proliferation of colon cancer cells.

Authors:  Zheng Wang; Jinxian Chen; Jianhua Sun; Zhe Cui; Hui Wu
Journal:  World J Surg Oncol       Date:  2012-06-26       Impact factor: 2.754

7.  Eukaryotic translation initiation factor 3, subunit C is overexpressed and promotes cell proliferation in human glioma U-87 MG cells.

Authors:  Jinmin Hao; Chaohui Liang; Baohua Jiao
Journal:  Oncol Lett       Date:  2015-03-26       Impact factor: 2.967

Review 8.  eIF3: a factor for human health and disease.

Authors:  Andreia Gomes-Duarte; Rafaela Lacerda; Juliane Menezes; Luísa Romão
Journal:  RNA Biol       Date:  2017-11-13       Impact factor: 4.652

9.  Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.

Authors:  Janet L Oblinger; Sarah S Burns; Elena M Akhmametyeva; Jie Huang; Li Pan; Yulin Ren; Rulong Shen; Beth Miles-Markley; Aaron C Moberly; A Douglas Kinghorn; D Bradley Welling; Long-Sheng Chang
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

Review 10.  Translation initiation factors and their relevance in cancer.

Authors:  Columba de la Parra; Beth A Walters; Phillip Geter; Robert J Schneider
Journal:  Curr Opin Genet Dev       Date:  2017-11-16       Impact factor: 5.578

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.